STRO SUTRO BIOPHARMA, INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1382101 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-34.4%
TTM net income YoY-74.9%
TTM EPS YoY-2,761.9%
Revenue 3-yr CAGR14.8%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-175.7%
Net margin-205.2%
FCF margin—
EBITDA margin-168.5%
Returns
ROE-1,810.0%
ROA-65.5%
ROIC (approx.)—
Asset turnover0.32x
Leverage & solvency
Liabilities / assets141.6%
Debt / equity—
Current ratio2.53x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.03x
Accruals ratio1.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $9.10M | $9.84M | $14.52M | $11.65M | $9.69M | $63.74M | $17.40M | $14.81M |
| R&D expense | $23.50M | $31.70M | $36.55M | $36.64M | $39.85M | $38.33M | $51.60M | $71.04M |
| SG&A expense | $7.54M | $7.83M | $7.58M | $8.66M | $8.74M | $10.34M | $13.27M | $9.03M |
| Operating income | -$21.96M | -$29.89M | -$29.66M | -$38.05M | -$48.46M | -$3.35M | -$68.51M | -$65.26M |
| Pretax income | -$31.49M | -$38.53M | -$38.50M | -$46.84M | -$56.86M | -$11.52M | -$75.96M | -$70.09M |
| Income tax | $0 | $1,000 | -$15,000 | -$82,000 | $0 | -$18,000 | $7,000 | $2.35M |
| Net income | -$31.49M | -$38.53M | -$38.48M | -$46.76M | -$56.86M | -$11.50M | -$75.97M | -$72.44M |
| EBITDA | -$20.71M | -$28.63M | -$28.38M | -$36.42M | -$46.56M | -$1.45M | -$66.61M | -$63.39M |
| EPS (basic) | -1.90 | -2.33 | -2.94 | — | -6.66 | -1.35 | -9.08 | — |
| EPS (diluted) | -1.90 | -2.33 | -2.94 | — | -6.66 | -1.35 | -9.08 | — |
| Weighted avg. shares (diluted) | 16.58M | 16.57M | 13.08M | — | 8.54M | 8.51M | 8.36M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $46.85M | $54.34M | $73.68M | $58.13M | $65.93M | $64.03M | $106.23M | $190.30M |
| Short-term investments | $95.33M | $110.01M | $128.88M | $83.30M | $101.67M | $141.11M | $142.74M | $126.59M |
| Receivables | $12.81M | $5.80M | $12.48M | $3.98M | $3.92M | $8.00M | $13.56M | $8.62M |
| Current assets | $159.50M | $175.65M | $220.97M | $150.93M | $182.11M | $231.63M | $287.41M | $343.31M |
| PP&E, net | $7.13M | $8.36M | $9.36M | $10.65M | $13.35M | $14.98M | $16.80M | $18.19M |
| Total assets | $176.65M | $194.46M | $241.99M | $173.83M | $209.66M | $262.36M | $321.43M | $387.21M |
| Current liabilities | $54.31M | $52.90M | $70.81M | $75.13M | $71.89M | $74.25M | $133.05M | $131.89M |
| Total liabilities | $309.18M | $297.78M | $308.88M | $306.28M | $296.93M | $294.47M | $347.24M | $342.61M |
| Shareholders' equity | -$132.54M | -$103.32M | -$66.89M | -$132.45M | -$87.27M | -$32.11M | -$25.81M | $44.60M |
| Shares outstanding | 16.60M | 16.58M | 16.57M | 8.58M | 85.10M | 84.72M | 84.35M | 8.31M |
| Cash flow statement | ||||||||
| Operating cash flow | -$22.45M | -$38.29M | -$42.26M | -$26.43M | -$38.19M | -$44.72M | -$67.88M | -$71.74M |
| Investing cash flow | $14.83M | $19.36M | -$45.26M | $18.70M | $39.99M | $2.58M | -$16.26M | $87.49M |
| Financing cash flow | $133,000 | -$418,000 | $103.08M | -$64,000 | $102,000 | -$60,000 | $66,000 | -$24,000 |
| Depreciation & amortization | $1.24M | $1.26M | $1.28M | $1.62M | $1.90M | $1.90M | $1.90M | $1.87M |
| Stock-based compensation | $2.16M | $2.01M | $1.56M | $1.66M | $1.55M | $5.26M | $5.54M | $5.92M |
Free plan shows the latest 8 periods; Pro shows all 39 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.